another newsletter alerting now : WallStreetHustler > Dear Wall Street Hustlers,
Our alert from Monday night on SOPV generated gains of over 5% trading in the ranges of 19 to 20 cents throughout the entire day on Tuesday. We believe that much larger profits could be seen in shortly within shares of SOPV so we want all of our members to continue to keep it on their watch lists.
We have now discovered a new stock in a multi-billion dollar industry that we feel could yield high returns on investments for savvy traders. This stock popped up on our screeners due to several different technical indicators and major recent developments that you will read about in the rest of this article.
The undervalued company that we at Wall Street Hustler would like to announce for Wednesday is
New Trade Alert - GENMED HOLDING CORP. (GENM.OB)
Please visit GENM's company website by clicking on the link below:
www.genmed.nl
GENM's Current PPS - 0.41
(Please make sure your email client is displaying images.)
GENM is a United States and Dutch based company focusing on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. The Company began its generic drug business in 2008 and today operates primarily through its 100% owned subsidiary Genmed B.V., which is registered in the Netherlands. The Company is led by an experienced management team and board who have considerable and highly relevant experience in product development, registration, sales, marketing, distribution, operations, and financial administration.
If you had to choose between an expensive name brand pharmaceutical or a low cost generic counterpart, which would you choose?
The following research proves continual increase in the amount of people choosing the generic brand over their more expensive counterparts. After reading the next two paragraphs you will quickly understand why GENM is poised for big growth in 2011.
In 2009, the global generics market generated approximately $84 billion in sales, according to US market data provider BCC Research, an increase of 7.7% from 2008 representing a compound annual growth rate of 11.9% for the five year period spanning 2004-2009.
According to Intercontinental Marketing Services Health (IMS Health), generic pharmaceuticals in the top eight markets, which include the United States, Canada, France, Germany, Italy, Spain, the United Kingdom and Japan, represent $62.6 billion dollars in revenue for 2009.
Projections estimate that sales of generic products could exceed $100 billion worldwide in 2011.This is why we are alerting you today!
GENM has positioned itself to market its generic pharmaceuticals to 365 million people who could benefit from low cost generic drugs.
GENM recently announced the release of new data regarding the size and the scope of the European Union's Generic drug market and that the countries of Western Europe alone represented a total market of 365 million+ people. According to this press release governmental pressure and new insurance policies are responsible for the increased demand generic medicines have experienced over their higher priced brand named counterparts. Once we became aware of this we knew we had to alert you on GENM right away.
The top ten global generic drug manufacturers and distributors account for approximately 66% of the market. Doug Long, vice-president, industry relations at IMS Health recently stated, "This means there are still many players out there that are pretty small and would be ripe for acquisitions or mergers...Everybody expects that there will be consolidation within the generic drugs industry..."
As GENM continues to expand its distribution network and begins to generate sales it could easily become an acquisition candidate for a major player or begin to merge with or acquire other companies in the generic pharmaceutical space. Any way you look at it will represent potential growth for the company and potential gains for investors savvy enough to get involved early.
The leg work has been completed in 2010 and 2011 will be a year of revenue growth for GENM!
During the year of 2010 GENM has obtained generic drug distribution licenses for the seven countries of:
· Netherlands
· Belgium
· Luxemburg
· Ireland
· United Kingdom
· Germany
· France
GENM expects purchase orders and initial shipments to begin within the first quarter of 2011.
The granting of these licenses allows GENM to market and distribute the drug, Paracetamol, otherwise known as Acetaminophen. (Paracetamol is the generic version of Tylenol which is widely recognized in the US or as Panadol which is most common to the United Kingdom.)
AI
Market Data 
Markets 
